The critical role of calcium signalling in processes related to cancer cell proliferation and invasion has seen a focus on pharmacological inhibition of overexpressed ion channels in specific cancer subtypes as a potential therapeutic approach. However, despite the critical role of calcium in cell death pathways, pharmacological activation of overexpressed ion channels has not been extensively evaluated in breast cancer. Here we define the overexpression of transient receptor potential vanilloid 4 (TRPV4) in a subgroup of breast cancers of the basal molecular subtype. We also report that pharmacological activation of TRPV4 with GSK1016790A reduced viability of two basal breast cancer cell lines with pronounced endogenous overexpression of TRPV4, MDA-MB-468 and HCC1569. Pharmacological activation of TRPV4 produced pronounced cell death through two mechanisms: apoptosis and oncosis in MDA-MB-468 cells. Apoptosis was associated with PARP-1 cleavage and oncosis was associated with a rapid decline in intracellular ATP levels, which was a consequence of, rather than the cause of, the intracellular ion increase. TRPV4 activation also resulted in reduced tumour growth in vivo. These studies define a novel therapeutic strategy for breast cancers that overexpress specific calcium permeable plasmalemmal ion channels with available selective pharmacological activators.
INTRODUCTION
The oncogenic process is associated with many molecular changes, including remodelling of specific calcium (Ca 2+ )-permeable ion channels. Ion channel expression changes are seen in different cancers including those of the breast, brain, prostate, ovary and colon. [1] [2] [3] [4] [5] [6] These include elevated levels of calcium channel, voltage-dependent, L-type, alpha 1D subunit (Ca v 1.3) in aggressive castrate-resistant prostate cancer compared with primary prostate cancer, 7 and pronounced increases in transient receptor potential (TRP) cation channel C6 (TRPC6) in high-grade human gliomas. 2 Ca 2+ channel expression can also differ between cancers of the same tissue origin but of different subtypes, for example, in breast cancer, elevated TRPV6 is more common in oestrogen receptor-negative breast cancer. 8 Calcium signalling regulates a variety of diverse cellular functions by precisely controlling the nature of the calcium signal. For example, the amplitude and duration of increases in cytosolicfree Ca 2+ ([Ca 2+ ] CYT ) and the cellular location of changes in Ca 2+ levels can all differentially regulate cellular processes. 9, 10 Selective regulation of the calcium permeable ion channels of the plasma membrane, which are encoded for by over 50 human genes, facilitates this precise control. 10 However, pathophysiologicalinduced alterations in the expression of specific Ca 2+ permeable ion channels, and subsequent alterations in Ca 2+ signalling can contribute to tumourigenesis through the promotion of specific hallmarks of cancer. Examples of these contributions include enhanced proliferation of prostate cancer cells via the remodelling of Orai3 Ca 2+ channel expression, 11 the reduction of MCF-7 breast tumour growth with Orai1 channel silencing, 12 and the association between TRPM7 channel expression and metastatic potential of breast cancer cells. 13 Identifying Ca 2+ channels that are overexpressed in breast cancers of the basal subtype would represent a therapeutic opportunity to exploit a pathophysiological change. Basal breast cancers are associated with poor prognosis and overlap with breast cancers negative for the oestrogen, progesterone and human epidermal growth factor receptor 2 (HER2) receptors, 14 limiting the use of effective hormonal and molecularly targeted therapies.
The intrinsic ability of the Ca 2+ ion to promote pathways key in cancer cell proliferation and invasion has led to a focus on inhibiting channel activity as the therapeutic paradigm. Such an approach is exemplified by both silencing and pharmacological inhibition of Orai1 attenuating the migration and invasion of breast cancer cells in vitro and in vivo. 15 An alternative therapeutic strategy is Ca 2+ channel activation and associated effects on processes sensitive to major and sustained elevations of intracellular free Ca 2+ , which include promotion of cell death or suppression of cell cycle progression. Disruption of ion gradients occurs in a variety of cell death pathways including apoptosis and the less studied oncosis. 17 Oncosis is associated with cell swelling and occurs in ischaemic cell death where ATP levels are compromised and the ability to maintain ion gradients is lost. 17, 18 Advantages inherent in the ion channel activation strategy in cancer include the ability to target dormant cancer cells and the apparent lack of opportunity for the cell to instigate a rapid adaptive response. An analogous phenomenon is seen in neurons, whereby overstimulation of the glutamate receptor results in intracellular free calcium overload and neuronal cell death. 19, 20 In stark contrast to the inhibitor approach, pharmacological activation does not require the ion channel to contribute to any oncogenic pathway for effectiveness. Using channel activation as a therapeutic approach in breast cancer has been limited by a lack of identified candidate calcium channels with pathophysiological overexpression for which selective pharmacological activators are available.
Recent studies suggest that TRP vanilloid 4 (TRPV4) levels are significantly higher in the basal molecular subtype of breast cancer 21 and that silencing of TRPV4 reduces metastatic potential of breast cancer cells. 21 TRPV4 is a well-characterised TRPV family member, and has been identified as a therapeutic target for a number of diseases prompting the development of selective pharmacological inhibitors and activators. [22] [23] [24] [25] In this study, we have sought to define the functional consequences of pharmacological activation of TRPV4 in basal breast cancer cells that endogenously overexpress TRPV4, and to assess the therapeutic potential of pharmacological ion channel activation in breast cancer therapy.
RESULTS
TRPV4 expression is enhanced in a subset of basal breast cancers Our analysis of the TCGA breast cancer database (845 tumours) showed that TRPV4 levels were significantly higher in the basal molecular subtype compared with HER2, luminal A (LumA) and luminal B (LumB) (Figure 1a ), consistent with a recent report using a different cohort. 21 We also identified clear heterogeneity in TRPV4 levels within basal breast cancers (Figure 1a) . Correlation between module eigengenes and common markers of breast cancer using WGCNA gene cluster analysis identified that the one module (of 19), termed 'ME red' (Supplementary Figure S1) , which was associated with TRPV4, was positively correlated with the basal markers KRT5 and EGFR, but negatively associated with the luminal markers ESR1, AR, PGR and FOXA1 (Figure 1b and Supplementary Figure S1 ). Some modules with similar basal signatures as ME red were not associated with TRPV4, for example, ME blue (Supplementary Figure S1 ). The expression level of genes in the ME red module (like TRPV4) were also enriched in basal breast cancers (Figure 1c ). Hierarchical clustering of TRPV4 and breast cancer relevant molecular marker levels ( Figure 1d ) provided insight into the marked heterogeneity of TRPV4 expression within the basal molecular subtype. However, this difference was not a consequence of major differences between the recently identified triple-negative breast cancer molecular subtypes (Supplementary Figure S2) .
Consistent with the diversity of TRPV4 levels in basal breast tumours, there was a subset of basal-like breast cancer cell lines with pronounced overexpression of TRPV4 (Figure 1e ). Heterogeneity was further reflected in lower expression of TRPV4 in basal A subtype compared with basal B subtype (Supplementary Figure S3) . Quantitative PCR analysis of basal-like breast cancer cell lines and non-malignant derived breast cell lines identified MDA-MB-468 and HER-2 amplified HCC1569 cells as having high levels of TRPV4 relative to MDA-MB-231 breast cancer cells, with low to undetectable levels of TRPV4 in non-malignant derived breast cell lines (Figure 1f ). Both RNA-Seq and quantitative PCR identified that the BT-20 basal-like breast cancer cell line had low levels of TRPV4 (Figures 1e and f) , consistent with the very low levels of TRPV4 seen in a small number of basal breast cancers (Figures 1a and d) . Collectively, these data indicate that elevated TRPV4 expression is predominately a feature of a specific subset of basal breast cancers.
Basal breast cancers with overexpression of TRPV4 are associated with augmented Ca 2+ influx mediated by the TRPV4 pharmacological activator GSK1016790A GSK1016790A is a selective TRPV4 activator 25 and was used in these experiments to examine the functional effect of TRPV4 activation in basal-like breast cancer cells. For the two cell lines with high levels of TRPV4, MDA-MB-468 ( Figure 2a ) and HCC1569 (Figure 2b) (Figure 3a ) and HCC1569 ( Figure 3b ). For MDA-MB-231 cells (Figure 3c ), which had low TRPV4 expression, and TRPV4-deficient BT-20 cells (Figure 3d ), the TRPV4 activator had no effect even at 10 μM. Further evidence of the dependence of TRPV4 expression levels on GSK1016790A effects was seen by the ability of TRPV4 small interfering RNA (siRNA) to attenuate both Ca 2+ influx and cell number (as assessed by nuclear count) decreases induced by submaximal concentrations of GSK1016790A in MDA-MB-468 breast cancer cells (Supplementary Figures S4a -S4f Figures S5c and s5d) . Indeed, no effect on the proliferation of either MDA-MB-468 or MDA-MB-231 cells was observed with the TRPV4 inhibitor RN1734 (1-10 μM, Supplementary Figure S6) . The association between Ca 2+ influx and reduced cell number is reflected by comparison of these two parameters in each assessed basal breast cancer cell line (Figure 3e) . Hence, the high [Ca 2+ ] CYT levels achieved in MDA-MB-468 and HCC1569 cells were clearly associated with the marked reduction in cell viability.
TRPV4 activation produces rapid and concentration-dependent cell death in TRPV4 overexpressing basal breast cancer cells Significant cell death in MDA-MB-468 cells was seen as early as 3 h in the presence of GSK1016790A with concentrations as low as 10 nM (Figure 4ai ). Approximately 30% of cells were propidium iodide permeable at 3 h with 100 nM GSK1016790A (Figures 4ai and aii) . The percentage of cell death was maximal by 3 h at 30 and 100 nM and was not increased after further incubation (6 h) at these higher concentrations (Figures 4bi and bii) . The rapid onset of cell death induced by GSK1016790A (Figure 2e ) suggested that at least one cell death mechanism was independent of gene expression changes in the cell death machinery. This led us to assess cell death mechanisms using morphological analysis and live cell imaging.
TRPV4 activator-mediated cell death is via oncosis and apoptosis Live cell imaging of MDA-MB-468 cells revealed clear differences in morphological changes in response to TRPV4 activation by GSK1016790A. Four major morphological changes were observed ( WGCNA results demonstrated that TRPV4 gene was in the Red Module (ME Red). Only the red module is shown and correlation coefficients and were calculated using Pearson correlation with P-values in parentheses. Red represents a positive correlation between ME and the specified breast cancer associated gene, whereas blue represents a negative correlation (colour scale and the other modules in Supplementary Figure S1 ). (c) Red Module ME expression levels in breast cancer molecular subtypes. ME expression was significantly higher in basal-like (basal) subtype compared with HER2-enriched (Her2), LumA and LumB subtypes. ***Po 0.001 compared with basal-like subtype using one-way ANOVA with Tukey's test. (d) Hierarchical clustering of TRPV4 and breast cancer relevant molecular marker normalised RNA-Seq gene expression from the TCGA cohort. 47 Levels are expressed on a red (high, +4) and blue (low, -4) colour scale. Breast cancer molecular subtypes represent basal-like (red) HER2-enriched (green), LumA (purple), LumB (light blue) and N-like (yellow). (e) TRPV4 and breast cancer relevant molecular markers were assessed by RNA-Seq in basal-like breast cancer cells line from the Klijn et al. 48 human cell line data set. Levels are shown on a red (high) and blue (low) colour scale and were hierarchically clustered via Manhattan-based averagelinkage. (f) TRPV4 mRNA levels in human basal breast cancer cell lines and non-malignant breast cell lines relative to 18S RNA and expressed as fold change compared with MDA-MB-231 breast cancer cells, data for basal breast cancer cells are mean ± s.d. from three independent cell passages.
(iii) cells that underwent initial and overt swelling followed by apparent plasma membrane rupture and collapse, consistent with oncosis (oncosis) and (iv) cells that underwent processes typical of failed mitosis/mitotic catastrophe (failed mitosis). Cells that did not meet the criteria for each morphological type were classified as 'mixed/other cell death', and often consisted of overlapping changes (for example, cell swelling and blebbing; see Supplementary Movies 1-3). Consistent with the assessment of propidium iodide permeability and viability studies, the proportion of surviving cells declined with increasing GSK1016790A concentrations (Figure 5b ). Oncosis was more apparent with greater TRPV4 activation, whereas the percentage of cells with apoptotic morphological changes was similar at 3, 10 and 100 nM GSK1016790A (Figure 5b ). Failed mitosis was not augmented or dependent on GSK1016790A and so was independent of TRPV4 activation (Figure 5b ). TRPV4 siRNA-mediated silencing showed that oncosis and apoptosis mediated by 3 nM GSK1016790A was TRPV4 dependent as was the pronounced oncosis induced by 100 nM GSK1016790A in MDA-MB-468 breast cancer cells Figure S7f) .
Oncosis is usually associated with cell swelling through an inability to maintain plasma membrane ion gradients because of reduced activity of ion pumps such as Na + /K + ATPases and plasma membrane Ca 2+ ATPases because of reduced mitochondrial function and subsequent decline of intracellular ATP levels. 17, 18, 27, 28 Given the rapid induction of oncosis and increases mediated by TRPV4 activation in these breast cancer cells (Figure 2a) . In order to identify the predominant source of ATP production during these high ion loads, the consequences of the oxidative phosphorylation inhibitor carbonyl cyanide 3-chlorophenylhydrazone and the glycolysis inhibitor 3-bromopyruvic acid 29, 30 were determined. Inhibition of oxidative phosphorylation by carbonyl cyanide 3-chlorophenylhydrazone had no significant effect on basal levels of ATP or the partial recovery of ATP levels 6 h after TRPV4 activation (Figure 5e ). Inhibition of glycolysis by 3-bromopyruvic acid produced a modest gradual (significant at 3 and 6 h) decline in basal ATP levels, but did not significantly reduce the partial recovery of ATP levels after TRPV4 activation (Figure 5e ). However, the combination of carbonyl cyanide 3-chlorophenylhydrazone and 3-bromopyruvic acid abolished the partial recovery of ATP levels after TRPV4 activation evident at 6 h, indicating that both pathways contribute to and co-compensate for each other during the ATP production that occurred during TRPV4 activation.
TRPV4 activation by GSK1016790A reduced basal breast cancer tumour cell growth in vivo To determine whether targeting TRPV4 could be a valid therapy for basal breast cancers overexpressing TRPV4, we examined the efficacy of GSK1016790A (0.225 or 0.3 mg/kg) against MDA-MB-468 tumours in vivo (Figure 6a ). These doses were above those previously used to target endogenous TRPV4 channels in mice and rats. 24, 31 GSK1016790A at 0.3 mg/kg significantly reduced the size of orthotopic MDA-MB-468 mammary fat pad xenografts (Figure 6a) . Mice from the high-dose cohort did not display any toxicity reported with intravenous infusion (0.3 mg/kg/5 min) of GSK1016790A 32 ( Figure 6b ). In the absence of an in vivo marker of oncosis, MDA-MB-468 tumours after 4 weeks of treatment with GSK1016790A were assessed for the expression of apoptosis markers. We did not observe significant changes in PARP-1 cleavage, caspase-7 cleavage or expression of the anti-apoptotic proteins Mcl-1 or XIAP by immunoblotting in these tumours (Supplementary Figure 8) . Future studies could develop methods for oncosis and/or assess apoptosis markers at earlier time points of xenograft growth during GSK1016790A treatment.
DISCUSSION
These studies have focused on the ion channel TRPV4 in basal breast cancer cells and the utility of pharmacological activation of TRPV4 as a therapeutic approach. TRPV4 has a role in a variety of mammalian cell types, often in the context of responding to exogenous and endogenous physical and chemical stimuli. 33 A variety of pharmacological modulators (inhibitors and activators) have been developed for diverse therapeutic purposes including the treatment of pain, 34 metabolic disorders associated with obesity, specific bladder and urinary tract disorders 22 and cardiovascular disease. 23 In contrast, the study of TRPV4 in cancer cells has not been extensive. Changes in the expression of other TRP channels are a characteristic of a variety of cancers that originate from different organs. For example, TRPC6 overexpression occurs in glioma as well as oesophageal, liver and breast cancers. 1, 2, 35, 36 In this study, we found that TRPV4 overexpression was predominantly associated with a subset of breast cancers within the poor prognosis basal molecular subtype.
Almost all studies of TRP channels in cancer have focused on the consequences of inhibiting the overexpressed channel. Such studies include those that identified that silencing of TRPC3 (overexpressed in some ovarian cancers) reduces in vivo tumour growth of an ovarian cancer cell line. 4 However, inhibition-focused therapeutic approaches require a maintained and substantial TRPV4 activation in breast cancer cells AA Peters et al contribution of the overexpressed protein to tumour cell proliferation and/or invasion. The availability of potent and specific TRP channel activators capable of producing maintained influx of Ca 2+ and Na + ions provides an opportunity to interrupt cancer cell processes and/or promote cell death pathways even for ion channels that do not contribute to a tumourigenic pathway. Activation of an overexpressed TRP channel and subsequent promotion of cell death represents a unique opportunity to target an overexpressed gene. However, assessment of this alternative approach has been limited. Activation of TRPM8 produces apoptosis in LNCaP prostate cancer cells, 37 but these studies required the use of non-selective TRPM8 activators, which have been associated with TRPM8-independent cell death. 38 The results of our studies focusing on TRPV4 in breast cancer cells and a highly selective TRPV4 activator, suggests that some cancer cells may overexpress a TRPV channel to such an extent, that selective pharmacological activation represents a viable therapeutic strategy.
The duality of the calcium signal as an essential element of life and death is respectively exemplified by the essential role of Ca 2+ transients during fertilisation and neuronal cell death during excitotoxicity. 9, 39, 40 The Ca 2+ ion achieves selective regulation of diverse cellular processes through decoding the nature of the calcium signal, such as its localisation and the duration and amplitude of increases. 10 Consistent with the importance of the duration and magnitude of [Ca 2+ ] CYT changes in inducing cell death in neurons, 41 our studies in basal breast cancer cell lines showed that the ability of TRPV4 pharmacological activation to reduce cell viability was related to the degree of TRPV4 overexpression, and as a consequence the magnitude of the [Ca 2+ ] CYT increase induced by TRPV4 activation in basal breast cancer cells.
Although high Ca 2+ loads are consistently associated with cell death, the nature of these Ca 2+ increases are linked to different cell death pathways. Large and rapid increases in [Ca 2+ ] CYT are associated with necrosis, 42 whereas activation of apoptotic pathways are often associated with increases in mitochondrial Ca 2+ and more sustained increases in [Ca 2+ ] CYT . 16, 43 TRPV4 activation in breast cancer cells with high endogenous levels of TRPV4 produced two distinct cell death pathways defined by clear morphological differences, oncosis and apoptosis.
Oncosis pathways are often associated with compromised ATP levels as a consequence of events such as ischaemia. 17 The decline in intracellular ATP leads to an inability of Ca 2+ and Na + pumps (ATPases) to sustain the required ion gradients for maintaining cellular integrity. 18, 28 Our studies showed that a major change in the ion gradient and cell swelling can be induced by activation of TRPV4 in some basal breast cancer cells. However, in contrast to some other inducers of oncosis, this is not driven by a gradual decline in intracellular ATP levels. For example, in NAD depletioninduced oncosis in six different cancer cell lines, the half-life for ATP depletion (which occurred before oncosis) is 430 h. 28 In contrast, our studies showed that oncosis with TRPV4 activation occurred with a median time of o6 h. GSK1016790A-induced oncosis produced a rapid decline in ATP levels, as ATPases consumed their substrate (ATP) to extrude Na + and Ca 2+ from the cell, in an attempt by the cell to achieve homeostasis. Similarly, cell death induced by the electroporation of cancer cell lines in the presence of high extracellular Ca 2+ is also associated with a rapid (~1 h) reduction of ATP levels. 44 The pharmacological activation of TRPV4 therefore represents a method to increase levels of [Ca 2+ ] CYT to produce cancer cell death, but in a manner suited to the targeting of cancer cells at sites not appropriate for electroporation. The ability of TRPV4 activation to produce cell death via multiple pathways in some basal breast cancer cells with very different times of onset, may bestow therapeutic benefits, such as less likelihood of the development of resistance mechanisms and promoting immune responses. Mechanisms responsible for some cells undergoing oncosis versus apoptosis include differences in the expression of TRPV4 or Ca 2+ efflux pumps between cells, which could influence the degree and rate of Ca 2+ increases, as well as differences in ATP levels or other factors that may influence oncosis and/or apoptosis induction.
TRPV4 activators promote the effectiveness of cisplatin therapy against mouse lung carcinoma cells in vivo through normalising of tumour vasculature. 24 Our identification of a subset of basal breast cancers with very high levels of TRPV4, and the ability of TRPV4 activators to directly suppress growth of breast cancer cell lines with these high levels of TRPV4 expression, suggests that there may be a group of women with breast cancer who may gain dual benefit from TRPV4 activators. This benefit would derive not just from improved delivery of current therapies through vascular changes mediated by TRPV4 activation as discussed above, 24 but also through the novel direct effects on breast cancer cell viability defined in these studies. Although these studies represent a proofof-concept for Ca 2+ permeable ion channel activation inducing cell death in breast cancer cells, the potential for TRPV4 activation to contribute to tumorigenic pathways should not be ignored. 21 Furthermore, TRPV4 activation therapy used to induce cell death and/or influence tumour vasculature and improve chemotherapeutic delivery, 24 should be restricted to breast cancers with high TRPV4 levels and would require maintained levels of TRPV4 activator to suppress tumour growth and/or promote cell death.
The studies presented herein highlight the opportunity for pharmacological activation of an overexpressed ion channel to be a viable approach to target specific cancer subtypes regardless of whether or not the ion channel contributes to tumour progression. The processes whereby ion channels contribute to excitotoxicity and neurological diseases may now be exploited to target specific cancers. The identification of ion channels that are overexpressed in specific cancers through increased gene copy number 8, 45 and/or other mechanisms 46 represents unique therapeutic opportunities across a range of cancer types.
MATERIALS AND METHODS
Assessment of TRPV4 levels in breast cancer molecular subtypes and basal breast cancer cell lines from the TCGA and Klijn et al.
(E-MTAB-2706) RNA-Seq databases, respectively
For assessment of TRPV4 and relevant molecular marker expression levels in the TCGA breast cancer data set, 47, 48 expression levels were defined as log2 row-mean-centred RNA-Seq by expectation maximisation. 49 The TCGA tumour cohort consists of 845 tumours with 140 basal-like (Basal), 67 HER2-enriched (HER2), 420 LumA, 194 LumB and 24 normal-like (N-Like) as determined by RNA-Seq based PAM50 allocations by the TCGA. 47 The WGCNA package in R was used to construct a breast cancer-specific gene co-expression network 50 from the top 10 000 most interconnected genes. Modules containing TRPV4 and other TRPV members were identified. The module eigengene for each module was calculated to assess the association between the modules and different breast cancer traits. The module eigengene is the first principal component representing the overall expression of a module, 51 or the weighted average expression value of all genes in a module. 52, 53 The module eigengene of each module was correlated to ten breast cancer associated genes (oestrogen receptor (ESR1), androgen receptor (AR), progesterone receptor (PGR), ERBB2/HER2, forkhead box protein M1 (FOXM1), forkhead box protein A1 (FOXA1), keratin 5 (KRT5), epidermal growth factor receptor (EGFR), enhancer of zeste homologue 2 (EZH2) and myeloid cell leukaemia 1 (MCL1)) that are used for clinical and molecular profiling. Correlations between the module eigengenes and the traits were calculated using Pearson correlation and significance was assessed using Student's t-test P-values.
The expression levels of the Red Module in breast cancer molecular subtypes were assessed using the module eigengene. The TCGA data set used for the WGCNA consisted of 402 clinical breast cancer samples (58 basal-like, 22 HER2-enriched, 213 LumA, 98 LumB and 11 N-like). Significance was assessed using the WGCNA package in R.
The expression levels of relevant molecular markers and TRPV4 were hierarchically clustered in Multiple Experiment Viewer (MeV) 54 via Manhattan-based average linkage with expression visualised through a heatmap, see Figure 1d . The PAM50 intrinsic molecular subtypes are indicated above the heatmap.
TRPV and breast cancer relevant molecular marker expression levels were assessed in breast cancer cell lines from Klijn et al. 48 Reads per kilobase per million RNA-Seq data for the cell lines was sourced from E-MTAB-2706 and relative expression was determined by log2 normalisation and row-mean-centreing of the reads per kilobase per million values across all cell lines, only basal shown. Cell line subtype was assigned by Klijn et al. and utilised in Supplementary Figure S3 . 48 Relative expression for TRPV4 and breast cancer relevant molecular markers were hierarchically clustered as described for Figure 1d . ] CYT and cell number), 7 × 10 3 cells per well (morphological assessment of cell death) or 1 × 10 4 cells per well (assessment of TRPV4 silencing by immunoblotting) using 0.1 μl per well DharmaFECT 4 according to the manufacturer's instructions, as previously described. 8 Effectiveness of TRPV4 silencing was assessed through assessment of TRPV4 mRNA levels relative to 18S ribosomal RNA 24 h after transfection and assessment of TRPV4 protein levels relative to β-actin 96 h after transfection.
Quantitative real-time RT-PCR RNA was isolated and reverse transcribed as previously described. 8 Quantitative PCR was performed using the Taqman Fast Universal PCR Master mix with TRPV4 (Hs01099348_m1) and 18s ribosomal RNA (4319413E) gene expression assays and a StepOnePlus Real-Time PCR system (Life Technologies, Carlsbad, CA, USA). Relative mRNA levels were calculated using the comparative C t method. 1-100 nM) or RN 1734 (1-100 μM) . The culture medium was replenished every 2 days. After 4 or 6 days, cell viability was assessed as described above.
Assessment of cell number and/or propidium iodide permeability Cells were stained with Hoechst 33342 plus propidium iodide and imaged as previously described. 57 Morphological assessment of cell death MDA-MB-468 cells were plated in 96-well plates at 3 × 10 3 cells per well or 7 × 10 3 cells per well for siRNA studies, after 24 h cells were treated with media containing 8% serum or siRNA and after 72 h cells were treated with vehicle (0.1% DMSO) or GSK1016790A (1-100 nM). Live cell imaging was performed using a JuLI Stage automated imaging system (NanoEntek, Seoul, Korea) with a 10x objective or for siRNA studies an Olympus IX81 Inverted fluorescent microscope (Notting Hill, VIC, Australia, with a Solent Scientific incubator (Segensworth, UK) and a Hamamatsu Orca Flash 2.8 Megapixel CMOS camera, Hamamatsu City, Japan) with a 10x objective. Images were acquired approximately every 60 s for 48 h. Cell morphology was characterised in cells in five pre-defined regions (104 × 140 μm) or for siRNA studies one identical region for each treatment type (169 × 169 μm). Cell morphology was defined as survived (cell mitosis or no morphological change at the end of the experiment), apoptosis (cell condensed and underwent blebbing and dispersed into at least five multiple distinct bodies; time of death was the time at which at least five distinct cellular packages were observed), failed mitosis (cell with multiple nuclei underwent blebbing after failed attempts of daughter cell separation), oncosis (a major and sudden change in cell contrast usually immediately preceded by swelling of the cell; time of death was the time at which the sudden change in contrast was observed), other (morphological changes associated with cell death that did not fit the aforementioned criteria; often mixed morphological changes, for example, swelling and blebbing). Cells that migrated out of the field or became obstructed from view were excluded.
Immunoblotting MDA-MB-468 cells were plated in 96-well plates (3 × 10 3 cells per well) for assessment of total and cleaved PARP1 or 6-well plates (2 × 10 5 cells per well) for all other targets (except TRPV4, see siRNA section above). Where specified cells were then treated with vehicle (0.1% DMSO) or GSK1016790A (3, 10 or 100 nM) for 24 h. Protein isolation, immunoblotting and quantification of the bands was performed as previously described. 58 For protein from orthotopic tumours fresh frozen tissues were crushed in liquid nitrogen and lysed with protein lysis buffer as previously described. 58 Antibodies were PARP-1 (9542, 1:1000), cleaved PARP (Asp214) (human specific) (9541, 1:1000), caspase -7 (C7) mouse mAb (human specific) (9494, 1:1000), Mcl-1 (D5V5L) rabbit mAb (39224, 1:1000), XIAP (D2Z8W) rabbit mAb (14334, 1:1000) and COX IV (3E11) rabbit mAb (4850, 1:5000) all from Cell Signaling (Danvers, MA, USA), and also TRPV4 (ab39260, 1:500, Abcam, Melbourne, VIC, Australia), β-actin (A5441, 1:10 000, Sigma-Aldrich), goat anti-rabbit (170-6515, Bio-Rad, Hercules, CA, USA) and goat anti-mouse (170-6516, Bio-Rad) horseradish peroxidase conjugate. PARP-1 cleavage was calculated as the percentage of the lower PARP-1 cleaved band relative to total PARP-1 protein.
Assessment of ATP levels
MDA-MB-468 cells were plated in opaque walled, clear bottom, 96-well plates (CellBIND surface, Corning) at 3 × 10 3 cells per well, after 96 h cells were pre-treated with 4 μM carbonyl cyanide 3-chlorophenylhydrazone, 100 μM 3-bromopyruvic acid, a combination or 0.1% DMSO (control) for 5 min before addition of 100 nM GSK1016790A. ATP levels were measured after 0.25, 1.5, 3 and 6 h using the CellTiter-Glo 2.0 Assay (Promega) according the manufacturer's guidelines and a Fluostar Omega micro-plate reader (BMG LABTECH, Offenburg, Germany).
Orthotopic breast model
The use of the orthotopic breast model was approved by the Animal Ethics Committee of the QIMR Berghofer (Chief investigator Professor Kum Kum Khanna; project number p674). Cohorts of female balb/c nude mice at 8 weeks of age (Animal Resources Centre, WA, Australia) with 50 mm 3 inguinal mammary fat pad tumours from 5 × 10 6 MDA-MB-468 cells implanted with 50% volume matrigel were randomly selected for treatment with vehicle or GSK1016790A (0.225 or 0.3 mg/kg; SigmaAldrich), intraperitoneally, for 4 weeks (5 days on, 2 days off, 10 mice per treatment was selected base on previous studies). The GSK1016790A was prepared in a final concentration of 1% DMSO, 30% β-cyclodextrin in saline (0.9%). Mice weights and tumour volume (calliper measurement) were measured twice per week (unblinded) and tumours were collected and stored at -80°C.
Statistical analysis
Statistical significance was assessed as described in the individual figure legends. All statistical analyses were performed using GraphPad Prism (La Jolla, CA, USA) or R.
